The global ankylosing spondylitis drugs market is forecast to reach USD 8.82 Billion by 2027, according to a new report by Reports and Data. Ankylosing spondylitis (AS) is a chronic condition that has no permanent cure. It can be defined as an inflammatory disease that results in some of the small bones in the spine (vertebrae) to fuse over time. The fusing of the small bones results in making the spine less flexible and can haunch it in a forward position. In case it affects the rib cage, the patient can have an issue with breathing deeply. The condition effects more men as compared to women. Symptoms and signs associated with condition usually initiates in adulthood. Inflammation associated with the condition may also occur in other parts of the body like eyes. Early signs associated with condition may include stiffness and pain in the lower back and hips, particularly in the morning and after prolonged sitting. Fatigue and neck pain are also common in AS. Though there is no cure to the condition with effective medication and treatment, the symptom can be managed and controlled. Various types of medications may help in stopping or delaying spinal problems and ease the pain & swelling. In regards to region, Europe, can be seen to occupy a prominent market share. The market position held by the region is attributed to high prevalence rate of the condition in this region, along with continuously expanding healthcare sector.

Get a sample of the report @

Some of the players profiled in the report are Merck & Co., Boehringer Ingelheim, UCB, Amgen, Janssen Biotech, Inc., Johnson & Johnson, Abbvie, Hetero, Zydus Cadila, and Izana Bioscience.

For the purpose of this report, Reports and Data have segmented the global Ankylosing Spondylitis Drugs market, according to Drug Type, Route of Administration, Distribution Channel, Application and Region:

Drug Type Outlook (Revenue, USD Billion; 2016-2027)

  • Nonsteroidal Anti-Inflammatory Drugs
  • Anti-Inflammatory Drugs
  • Immunosuppressive Drugs
  • TNF blockers
  • JAK Inhibitors
  • Steroids
  • Biologics
  • Others

Route of Administration Outlook (Revenue, USD Billion; 2016-2027)

  • Parenteral
  • Oral

Distribution Channel Outlook (Revenue, USD Billion; 2016-2027)

  • Hospitals Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Application Outlook (Revenue, USD Billion; 2016-2027)

  • Adults
  • Juveniles

Market Segmentation by Regions:

North America (U.S., Canada)

Europe (U.K., Italy, Germany, France, Rest of EU)

Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)

Latin America (Chile, Brazil, Argentina, Rest of Latin America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

Key Point Summary of the Report:

The global Ankylosing Spondylitis Drugs market research report is an investigative study offering key insights into the latest growth trends, developments, technological and product advancements, and the research and development scenario. The report also covers the market aspects that directly influence the growth of the market. These features include strategies undertaken by the prominent players, their expansion tactics, and the product portfolios of the companies, and micro and macro-economic factors.

The study also analyses the crucial market aspects, including R&D, product launches and brand promotions, mergers and acquisitions, collaborations, joint ventures, and the growth pattern on both regional and global levels. The report offers an in-depth evaluation of factors such as cost, capacity, rates of production and consumption, gross revenue, profit margin, demand and supply ratio, import/export, market share, market size, and market trends.

To summarize everything stated above, the report offers key insights into the Ankylosing Spondylitis Drugs market to allow the reader to gain a complete understanding of the Global Ankylosing Spondylitis Drugs Market through accurate estimations, a panoramic view of the market scenario, competitive landscape, factors influencing the growth of the market, driving factors, restraints, regulatory framework, growth prospects and opportunities, and factors propelling the market forward. The research study offers an in-depth view of the industry to offer a competitive edge to the reader and help them in formulating beneficial investment plans. The report provides a comprehensive overview of the market with facts relating to the past, present, and future of the Global Ankylosing Spondylitis Drugs Market.

Table of content:

Chapter 1. Market Synopsis

    1.1. Market Definition

1.2. Research Scope & Premise

1.3. Methodology

1.4. Market Estimation Technology

Chapter 2. Executive Summary

2.1. Summary Snapshot, 2018-2027

Chapter 3. Indicative Metrics

Chapter 4. Ankylosing Spondylitis Drugs Market Segmentation & Impact Analysis

4.1. Ankylosing Spondylitis Drugs Market Segmentation Analysis


Chapter 11. Company Profiles

    11.1. Merck & Co.

           11.1.1. Company Overview

11.1.2. Financial Performance

11.1.3. Technology Insights

11.1.4. Strategic Initiatives

    11.2. Boehringer Ingelheim

            11.2.1. Company Overview

11.2.2. Financial Performance

11.2.3. Technology Insights

11.2.4. Strategic Initiatives

    11.3. UCB

11.3.1. Company Overview

11.3.2. Financial Performance

11.3.3. Technology Insights

11.3.4. Strategic Initiatives

    11.4. Amgen

11.4.1. Company Overview

11.4.2. Financial Performance

11.4.3. Technology Insights

11.4.4. Strategic Initiatives

    11.5. Janssen Biotech, Inc.

11.5.1. Company Overview

11.5.2. Financial Performance

11.5.3. Technology Insights

11.5.4. Strategic Initiatives

    11.6. Johnson & Johnson

11.6.1. Company Overview

11.6.2. Financial Performance

11.6.3. Technology Insights

11.6.4. Strategic Initiatives

    11.7. Abbvie

            11.7.1. Company Overview

11.7.2. Financial Performance

11.7.3. Technology Insights

11.7.4. Strategic Initiatives

    11.8. Hetero

11.8.1. Company Overview

11.8.2. Financial Performance


Request for Customization of Report @

Thank you for reading our report. For more inquiry or query on customization, kindly get in touch with us. Our team will ensure you get the best report suited to your needs.

Contact Us:

John W
Head of Business Development
Direct Line: +1-212-710-1370
E-mail: [email protected]
Reports and Data | Web:
Connect with us:  Facebook | LinkedIn | Twitter

Leave a comment

Your email address will not be published. Required fields are marked *